Notice ID: 86e139730dfa44fbbcdadd0f048914b0Presolicitation
Notice of Intent - Sole Source to PEPperPRINT GmbH
Archived on May 7, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 10:00 AM UTC−04:00
- Posted
- April 28, 2020
- Notice type
- Presolicitation
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION
Notice details
- Office
- FDA OFFICE OF ACQ GRANT SVCS
- Last updated
- Sep 9, 2025
Identifiers
- Solicitation number
- FDA-NOI-SS-1226443
- Notice ID
- 86e139730dfa44fbbcdadd0f048914b0
Description
The U.S. Food & Drug Administration (FDA) intends to issue a Sole Source follow-on award to the PEPperPRINT GmbH for continuing existing validation studies. The Government intends to issue a sole source award in accordance with FAR 6.302-1, only one responsible source and no other will satisfy the agency requirements for the above stated service. FDA aims to provide tools to enable the development of assays that can provide unambiguous diagnosis of recent vs. past ZIKV infection through peptide-specific differentiation of IgM or IgG responses. These specific peptides will also help distinguishing ZIKV from its closely related viruses. The scope of the existing work is to continue ongoing validation studies which was started in 2016 under contract number 1U01FD006279. Peptides obtained by preliminary screening of full viral proteomes in research project were more numerous than expected due to underestimation of cross-reactivity. Due to the restriction imposed by the available funds, only partial count of the peptides obtained in the discovery screening were selected for the validation studies. In 2019, a first validation step study was conducted to continue the studies of the remainder of the peptides already identified in the original screening stage. Under this requirement, FDA is requesting to complete the final validation of about the remainder of the peptides. PEPperPRINT GmbH has previously conducted the validation studies for this requirement under the previous FDA contract. This is continuation of the same research project and so the work will be continued by the same company. The specimens used in the study were characterized for IgM/IgG antibodies against the virus under study by FDA cleared/ authorized assays as a first choice. This requirement aims to perform comparative proteome-wide epitope mapping analyses of ZIKV and other related viruses specific epitopes with single amino acid resolution. This will be a firm fixed price award.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
FDA-NOI-SS-1226443- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- Pre-SolicitationCurrentApr 28, 2020
Notice of Intent - Sole Source to PEPperPRINT GmbH
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
FDA-NOI-SS-1226443
Archive Date
May 7, 2020
Office Address
Beltsville, MD, 20705